desvenlafaxine 50 mg

DRUG2 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Mochida Pharmaceutical Company, Ltd.

Conditions

Depressive Disorder, MajorMajor Depressive Disorder

Phase 3

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

CompletedNCT00300378

Wyeth is now a wholly owned subsidiary of PfizerDepressive Disorder, Major

Start: 2006-03-31End: 2007-01-31Target: 480Updated: 2007-12-05

A Study of MD-120 in Patients With Depression

CompletedNCT04345471

Mochida Pharmaceutical Company, Ltd.Major Depressive Disorder

Start: 2020-05-18End: 2022-09-14Updated: 2024-02-29

Related Papers

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials

Journal of Clinical Psychopharmacology2021-06-291 citations

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

2016-01-133 citations

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

The Primary Care Companion For CNS Disorders2015-06-0411 citations

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.

2015-03-267 citations